Table 1.
Relevant demographic, clinical and medical history variables of de-identified patients
| Patient ID: sample ID/spinal level (pain state)a | Age, race (sex)b | Primary tumour (prior chemotherapy/systemic treatments) | Neuropathic/radicular symptom length (VAS at maximal intensity) |
|---|---|---|---|
| 21: T3L (P), T6L (P) | 59, W (M) | Metastatic chordoma (N) | >1 mo, <6 mo (6.0) |
| 22: T10L (N), T10R(P) | 61, O (M) | Renal cell carcinoma (N) | >6 mo, <12 mo (6.0) |
| 23: T2L (P), T2R (P) | 57, W (F) | Non-small cell lung carcinoma (N) | >1 mo, <6 mo (NA) |
| 24: T2R (P) | 70, B (M) | Adenoid cystic carcinoma (N) | >12 mo (8.1) |
| 25: T12R (N) | 60, W (F) | Endometrial carcinoma (Y: carboplatin/doxorubicin, cisplatin/gemcitabine) | NA (6.7) |
| 26: T3R (P), T4R (P) | 55, W (M) | Non-small cell lung carcinoma (Y: cisplatin/taxol) | >6 mo, <12 mo (8.4) |
| 29: T8R (N) | 79, B (M) | Dedifferentiated sarcoma (N) | >12 mo (1.9) |
| 30: T3R (P) | 70, O (M) | Renal cell carcinoma (Y: sunitinib) | >12 mo (6.5) |
| 31: T7L (P), T7R (P) | 66, W (M) | Chondrosarcoma (N) | >12 mo (9.7) |
| 32: T5R (P) | 66, B (F) | Non-small cell lung carcinoma (N) | >1 mo, <6 mo (8.6) |
| 33: T3R (U), T4R (U) | 42, W (F) | Breast carcinoma (Y: docetaxel, carboplatin, trastuzumab, pertuzumab, adotrastuzumab emtansine, alpelisib) | >1 mo (6.9) |
| 34: T5R (P), T6R (P) | 41, AI (M) | Fibrous dysplasia (N) | >12 mo (6.2) |
| 35: T10L (P), T10R(N) | 64, W (M) | Renal cell carcinoma (N) | >6 mo, <12 mo (4.7) |
| 37: T2R (P) | 73, O (F) | Renal cell carcinoma (Y: pazopanib, nivolumab) | >1 mo, <6 mo (9.4) |
| 38: T7L (P), T7R (P) | 63, U (F) | Metastatic melanoma (N) | >1 mo, <6 mo (8.6) |
| 39: T8L (N), T8R (P) | 59, AI (M) | Renal cell carcinoma (N) | >1 mo, <6 mo (8.7) |
| 40: T4L (P) | 59, W (M) | Non-small cell lung carcinoma (N) | NA (10) |
| 41: T7R (P) | 55, W (F) | Adenocarcinoma (N) | >6 mo, <12 mo (10) |
| 42: T7L (P), T7R (P) | 64, W (F) | Leiomyosarcoma (Y: docetaxel, gemcitabine) | NA (4.5) |
| 44: T10R (N), T11L (N), T11R (N) | 56, W (M) | Metastatic melanoma (Y: TIP-287 (taxane), cisplatin, ipilumumab, vemurafenib, dabrafenib, pazopanib) | NA (7.1) |
| 45: T10L (N), T11R (P) | 68, W (M) | Renal cell carcinoma (Y: nivolumab, cabozanitinib) | NA (9.7) |
| 46: T8R (P) | 60, W (F) | Renal cell carcinoma (Y: pazopanib) | NA (8.8) |
| 47: T7L (P), T7R (P) | 65, W (M) | Multiple myeloma (Y: bortezomib, Cyp, pamlid/thalid/lenalidomide) | >1 mo, <6 mo (8.2) |
| 61: T5L (N), T5R (N) | 37, W (M) | Renal cell carcinoma (Y: pazopanib, nivolumab, everlimus, tremelimumab) | NA (7.3) |
| 64: T7L (P), T7R (U), T8R (U) | 71, W (M) | Prostate carcinoma (Y: cabazitaxel, abiraterone, docetaxel/carboplatin, doxorubicin, paclitaxel) | >6 mo, <12 mo (9.9) |
| 66: T12L (N), T12R (P) | 50, W (M) | Colon carcinoma (Y: FOLFOX, iriniteca/erbitux, vectibix) | <1 mo (9.9) |
| 67: T4L (N), T4R (N) | 65, W (F) | Breast carcinoma (N) | NA (8.6) |
| 69: T10L (N) | 65, A (F) | Hepatocellular carcinoma (N) | NA (8.2) |
| 71: T7L (P), T7R (P) | 65, O (F) | Cholangiocarcinoma (gemcitabine/cisplatin) | >3 mo (9.7) |
| 80: T2R (N) | 68, W (M) | Renal cell carcinoma pazopanib, nivolumab/ipilimumab | NA (9.9) |
| 81: T5R (P), T6R (P) | 33, W (M) | Renal cell carcinoma: pembolizumab | >3 mo (8.1) |
| 83: T8R (P) | 58, W (M) | Malignant melanoma:immunotherapy | 3 mo (9.4) |
| 84: T4L (P), T5L (P) | 56, W (M) | Renal cell carcinoma:immunotherapy | 3 mo (6.8) |
| 85: T3L (P), T3R (P), T5L (P), T5R (P) | 39, W (F) | Colon carcinoma (NA) | 3 mo (9.5) |
| 86: T6R (P), T7R (P) | 40, B (F) | Chondrosarcoma (N) | 24 mo (8.6) |
| 87: T5L (N) | 55, B (M) | Colon carcinoma (Y: irinotecan/cetuximab) | NA (8.9) |
| 88: T10R (P) | 72,W (M) | Hurthle cell thyroid carcinoma (Y: radio-iodine 200) | 1 mo (8.7) |
| 89: T6L (N), T6R (N) | 63, W (F) | Unknown (N) | NA (5.8) |
| 90: T8R (N) | 59, W (M) | Ewing’s sarcoma (vincristine, doxirubicin, ifosfamide; etopisde, ifosfamide) | >3 mo (7.9) |
| 91: T4L (P), T4R (P), T5L (P) | 77, W (M) | Prostate carcinoma (bicalutamide, leuprolide) | >3 mo (9.1) |
| AIDC-291: T12U (N) | 34, W (M) | Cause of death: CVA/stroke (N) | NA (NA) |
mo = months; VAS = visual analogue scale.
Level: L = left; R = right; T = thoracic; U = unknown. Pain state: N = no pain; P = pain; U = undetermined—in sample-associated dermatome.
Race: A = Asian; AI = American Indian; B = Black; O = Other; W = White. Sex: F = female; M = male.